Obesity and Dyslipidemia.
Nussbaumerova B, Rosolova H.
Curr Atheroscler Rep. 2023 Dec;25(12):947-955. doi: 10.1007/s11883-023-01167-2. Epub 2023 Nov 18.
Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook.
Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M, Hermans MP, Pandey RC, Ray KK, Tokgözoglu L, Zambon A, Berrou JP, Farnier M.
Atherosclerosis. 2023 Oct;383:117312. doi: 10.1016/j.atherosclerosis.2023.117312. Epub 2023 Sep 30.
A Modern Approach to Dyslipidemia.
Berberich AJ, Hegele RA.
Endocr Rev. 2022 Jul 13;43(4):611-653. doi: 10.1210/endrev/bnab037.
Nephrotic Syndrome.
Politano SA, Colbert GB, Hamiduzzaman N.
Prim Care. 2020 Dec;47(4):597-613. doi: 10.1016/j.pop.2020.08.002. Epub 2020 Sep 26.
Advances in Treatment of Dyslipidemia.
Dybiec J, Baran W, Dąbek B, Fularski P, Młynarska E, Radzioch E, Rysz J, Franczyk B.
Int J Mol Sci. 2023 Aug 27;24(17):13288. doi: 10.3390/ijms241713288.
Treating Dyslipidemia for the Primary and Secondary Prevention of Stroke.
Barkas F, Milionis H.
Semin Neurol. 2017 Jun;37(3):286-293. doi: 10.1055/s-0037-1603511. Epub 2017 Jul 31.
Global epidemiology of dyslipidaemias.
Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL.
Nat Rev Cardiol. 2021 Oct;18(10):689-700. doi: 10.1038/s41569-021-00541-4. Epub 2021 Apr 8.
Current pharmacotherapeutic options for primary dyslipidemia in adults.
Cicero AFG, Landolfo M, Ventura F, Borghi C.
Expert Opin Pharmacother. 2019 Jul;20(10):1277-1288. doi: 10.1080/14656566.2019.1604687. Epub 2019 May 6.
Inclisiran: First Approval.
Lamb YN.
Drugs. 2021 Feb;81(3):389-395. doi: 10.1007/s40265-021-01473-6.
Meta-Analysis of Dyslipidemia and Blood Lipid Parameters on the Risk of Primary Open-Angle Glaucoma.
Huang G, Wang J, Li L, Gao Y, Yan Y.
Comput Math Methods Med. 2022 Sep 21;2022:1122994. doi: 10.1155/2022/1122994. eCollection 2022.
